1717 Business established by Ichibei Fushimiya. 1934 Ono Ichibei Shoten established as an unlimited partnership. 1947 Ono Pharmaceutical Co., Ltd. established. 1962 Shares listed on the Osaka Securities Exchange. 1963 Shares listed on the Tokyo Stock Exchange. 1968 Central Research Institute (now the Minase Research Institute) constructed. Company succeeds at world's first synthesis of prostaglandin (PG). 1973 Prostarmon-F, the world's first PG pharmaceutical, launched. 1975 Fujiyama Plant constructed. 1977 FOY, protease inhibitor, launched. 1982 London office opened. 1984 New head office building constructed. 1985 Fukui Safety Research Institute constructed. Foipan, oral protease inhibitor, launched. 1987 New Minase Research Institute (previously Central Research Institute) building constructed. 1988 Central Distribution Center constructed. Cataclot, the world's first thromboxane synthetase inhibitor, launched. 1989 Main building for Minase Research Institute constructed. 1990 Seattle office opened. 1992 Kinedak, aldose reductase inhibitor, launched. 1994 Seoul office (current Seoul Branch) opened. 1995 Tokyo Branch Office relocated. Onon, world's first leukotriene receptor antagonist, launched. 1998 Local offices in the US and UK dissolved. Ono Pharma UK Ltd established in the UK and Ono Pharma USA, Inc. established in the US. 1999 Construction (1st term) on Fujiyama Plant No. 7 completed. 2000 Onon Dry Syrup, the first leukotriene receptor antagonist for pediatric use, launched. 2002 Elaspol, the World's First Drug for Acute Lung Injury, launched. Onoact, Japan's First Short-Acting Selective β1 Blocker, launched. 2003 Tsukuba Research Institute constructed.